National Project Implementation Plan - NVBDCP
National Project Implementation Plan - NVBDCP
National Project Implementation Plan - NVBDCP
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
agent of the DMO) will annually sample the LMIS data and verify the chain of<br />
transactions from the time of delivery in the district down to service delivery<br />
points in PHCs to authenticate the information. This same agent will assess the<br />
quality of ACT/RDT, ‘rk39’ or first line medicines for kala-azar and vector<br />
control supplies storage facilities. The LMIS will not track the distribution of<br />
LLINs and ACTs to patients as that is the role of the HMIS. The MOHFW is in<br />
the process of establishing a comprehensive LMIS for the health sector with<br />
support from DFID in three states. Two of these states where such piloting is<br />
taking place are also malaria endemic states proposed to be included under the<br />
project (Orissa and Madhya Pradesh) and efforts would be made to ensure<br />
integration of the project LMIS with this initiative. RNTCP has hired the services<br />
of Consultant agency for supply chain management for keeping track of<br />
inventory down from block level to state level. The same agency shall be hired<br />
by <strong>NVBDCP</strong> for similar work.<br />
(c) System to monitor the quality of rapid diagnostic tests and medicines to<br />
ensure their quality upon delivery and at point of use<br />
<strong>NVBDCP</strong> has prepared a protocol for monitoring the quality RDTs in accordance<br />
with WHO recommendations and technical documents. This will now translate<br />
to an action plan, which includes the training of a limited number of laboratory<br />
technicians in each state, who will sample and control RDTs. Similarly, a<br />
protocol will be established for quality assurance of antimalarial medicines<br />
(especially ACTs), which will be sampled according to established and approved<br />
protocols in the context of the work described under (d). <strong>NVBDCP</strong> will seek<br />
Consultant from WHO for this purpose. Quality assurance of ‘RDK and first line<br />
drugs used in the treatment of kala-azar will be undertaken with the help of<br />
RMRI, Patna. Help will also be taken from the Regional Directors, ROHFW for<br />
implementation.<br />
(d) Monitoring of parasite resistance to antimalarial medicines, in particular<br />
the first-line ACT (artesunate plus sulfadoxine-pyrimethamine), Miltefosine and<br />
vector resistance to insecticides<br />
With the adoption of an ACT including the long-acting sulfadoxinepyrimethamine<br />
(SP) as a component, close resistance monitoring including<br />
molecular markers becomes essential. This work will be led by NIMR, which has<br />
established a protocol in collaboration with <strong>NVBDCP</strong>. ACT therapeutic efficacy<br />
and molecular markers for SP resistance will be collected from 30 sites, where<br />
patients will be sampled and examined every second year in each site. In<br />
addition, susceptibility of P.vivax to chloroquine will be monitored in 3-4 of<br />
these sites. Monitoring of resistance to miltefosine will be undertaken in three<br />
(3) sites by rotation and RMRI will be involved in oversight of this activity.<br />
Monitoring of insecticide resistance across the country has been weak for many<br />
years despite the availability of trained entomologists in research centres. A<br />
protocol has been established by NIMR in collaboration with <strong>NVBDCP</strong> to assess<br />
over a 5-year period, the susceptibility of anopheline vectors to the main<br />
86